MiR-124-5p Inhibits the Progression of Gastric Cancer by Targeting MIEN1

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2020 Dec 22

PMID 33349155

Citations 4

Authors

Feng Liang

Hongyan Zhang

Yuxuan Qiu

Qianru Xu

Kaiyu Jian

Lin Jiang

Fei Wang

Xin Lu

Affiliations

Soon will be listed here.

Abstract

Objective: To observe the effect of miR-124-5p on progression of gastric cancer (GC) and explore the targeting mechanism.

Methods: After collecting the specimens, we used real-time fluorescence quantitative PCR to detect the miR-124-5p level of GC tissue and corresponding adjacent tissue. Then MTT test and scratch wound-healing assay were hired to evaluate the influence of miR-124-5p in GC cell (SGC-803 and SGC7901) migration and proliferation ability. The binding of miR-124-5p to migration and invasion enhancer 1 (MIEN1) was detected through dual luciferase reporter gene experiment and western blot was utilized to assay the protein level of MIEN1.

Results: Compared with adjacent tissues, miR-124-5p level in GC tissues was lower significantly. MiR-124-5p mimic inhibited the metastasis and proliferation ability of SGC7901 cells and miR-124-5p inhibitor promoted the migration and proliferation ability of SGC803 cells. In addition, miR-124-5p targeted MIEN1 and negatively modulated the MIEN1 expression in SGC-803 and SGC7901 cells. Silencing MIEN1 negatively regulated the metastasis and proliferation ability of SGC7901 cells.

Conclusion: MiR-124-5p inhibited the GC cell proliferation and metastasis phenotypes through MIEN1, which probably becomes a novel molecular target for clinical GC treatment.

Citing Articles

Mechanistic insights into the role of traditional Chinese medicine in treating gastric cancer.

Chen Z, Yu T, Wang Y, Li J, Zhang B, Zhou L Front Oncol. 2025; 14:1443686.

PMID: 39906672 PMC: 11790455. DOI: 10.3389/fonc.2024.1443686.

Function of microRNA‑124 in the pathogenesis of cancer (Review).

Liu Y, Yang Y, Wang X, Yin S, Liang B, Zhang Y Int J Oncol. 2023; 64(1).

PMID: 38038165 PMC: 10705041. DOI: 10.3892/ijo.2023.5594.

Molecular characteristics of gastric cancer with amplification.

Cao D, Xu H, Li L, Ju Z, Zhai B Heliyon. 2023; 9(8):e18654.

PMID: 37554835 PMC: 10405018. DOI: 10.1016/j.heliyon.2023.e18654.

Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3.

Li J, Chen Z, Xiao W, Liang H, Liu Y, Hao W J Cell Mol Med. 2023; 27(21):3259-3270.

PMID: 37525498 PMC: 10623538. DOI: 10.1111/jcmm.17893.

The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis.

Yu Q, Chen W, Li Y, He J, Wang Y, Yang S Bioengineered. 2022; 13(3):4717-4729.

PMID: 35212603 PMC: 8974013. DOI: 10.1080/21655979.2022.2031398.

References

Katz E, Dubois-Marshall S, Sims A, Faratian D, Li J, Smith E . A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010; 103(3):401-10. PMC: 2920017. DOI: 10.1038/sj.bjc.6605763. View

Liu F, Hu H, Zhao J, Zhang Z, Ai X, Tang L . miR-124-3p acts as a potential marker and suppresses tumor growth in gastric cancer. Biomed Rep. 2018; 9(2):147-155. PMC: 6036824. DOI: 10.3892/br.2018.1113. View

Evans E, Henn A, Jonason A, Paris M, Schiffhauer L, Borrello M . C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Mol Cancer Ther. 2006; 5(11):2919-30. DOI: 10.1158/1535-7163.MCT-06-0389. View

Pogue-Geile K, Kim C, Jeong J, Tanaka N, Bandos H, Gavin P . Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst. 2013; 105(23):1782-8. PMC: 3848987. DOI: 10.1093/jnci/djt321. View

Mohr A, Mott J . Overview of microRNA biology. Semin Liver Dis. 2015; 35(1):3-11. PMC: 4797991. DOI: 10.1055/s-0034-1397344. View

Rajendiran S, Kpetemey M, Maji S, Gibbs L, Dasgupta S, Mantsch R . MIEN1 promotes oral cancer progression and implicates poor overall survival. Cancer Biol Ther. 2015; 16(6):876-85. PMC: 4622880. DOI: 10.1080/15384047.2015.1040962. View

Duraes C, Almeida G, Seruca R, Oliveira C, Carneiro F . Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. Virchows Arch. 2014; 464(3):367-78. DOI: 10.1007/s00428-013-1533-y. View

Fabian M, Sonenberg N, Filipowicz W . Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010; 79:351-79. DOI: 10.1146/annurev-biochem-060308-103103. View

Dasgupta S, Wasson L, Rauniyar N, Prokai L, Borejdo J, Vishwanatha J . Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene. 2009; 28(32):2860-72. PMC: 2726905. DOI: 10.1038/onc.2009.145. View

10.

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

11.

Kushwaha P, Gupta S, Singh A, Kumar S . Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis. Front Oncol. 2019; 9:868. PMC: 6738349. DOI: 10.3389/fonc.2019.00868. View

12.

Qu H, Xu W, Huang Y, Yang S . Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011; 12(5):1117-25. View

13.

Yu H, Zhang J, Wen Q, Dai Y, Zhang W, Li F . MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer. Exp Ther Med. 2018; 16(4):3249-3255. PMC: 6125861. DOI: 10.3892/etm.2018.6569. View

14.

Uprak T, Attaallah W, Ataizi Celikel C, Ayranci G, Yegen C . HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters. Ulus Cerrahi Derg. 2015; 31(4):207-13. PMC: 4674041. DOI: 10.5152/UCD.2015.2964. View

15.

Chen Q, Lu G, Cai Y, Li Y, Xu R, Ke Y . MiR-124-5p inhibits the growth of high-grade gliomas through posttranscriptional regulation of LAMB1. Neuro Oncol. 2014; 16(5):637-51. PMC: 3984553. DOI: 10.1093/neuonc/not300. View

16.

Dasgupta S, Cushman I, Kpetemey M, Casey P, Vishwanatha J . Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. J Biol Chem. 2011; 286(29):25935-46. PMC: 3138290. DOI: 10.1074/jbc.M111.254599. View

17.

Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A . High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010; 12(3):R25. PMC: 2917012. DOI: 10.1186/bcr2568. View

18.

Li D, Wei Y, Wang D, Gao H, Liu K . MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. Biochem Biophys Res Commun. 2016; 472(3):465-70. DOI: 10.1016/j.bbrc.2016.01.163. View

19.

Hartgrink H, Jansen E, van Grieken N, van de Velde C . Gastric cancer. Lancet. 2009; 374(9688):477-90. PMC: 4613761. DOI: 10.1016/S0140-6736(09)60617-6. View

20.

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View